Corporate and strategic investors

Pay the right price,
then show the market what you bought

Whether you're acquiring a business or taking a strategic stake, we help you price the deal with confidence and then show your shareholders the value it creates. We support you from the first look at a target to the first set of financial statements after completion, for private companies and listed groups alike.

Contact us
01

Stage 1 · Pre-dealIndicative Valuation

An early, independent view of what a potential target could be worth, so you can decide whether to pursue it before committing time and due diligence costs.

Key risks we help you avoid
  • Anchoring on the seller's asking price
  • Spending time and due diligence costs on targets that won't meet your return or strategic criteria
In more detail

We build an independent indicative range based on the target's business, its sector and how comparable companies and transactions are priced, and highlight the drivers and risks that should shape your view of value.

02

Stage 2 · Non-binding offerFull Valuation

An independent valuation of the target that tests the seller's projections, benchmarks performance against peers and gives you a defensible basis for your offer.

Key risks we help you avoid
  • Paying for optimistic seller projections the business is unlikely to deliver
  • Paying away your own synergies to the seller
  • Risks such as customer concentration or key-person dependence not reflected in the price
In more detail

Sellers and their advisers naturally present the business in its best light. Before you make an offer, we build an independent view of value: testing the seller's projections against historical performance and the market, benchmarking against comparable companies and transactions, and identifying the risks that should be reflected in the price.


We also help you separate the value of the business as it stands from the value of synergies only you can create, so you can decide how much of that upside, if any, you are willing to pay for. If required, we can present the valuation results together with you to your Board.


If you are an SGX-listed company and the transaction requires an independent valuation under Chapter 9 (Interested Person Transactions) or Chapter 10 (Significant Transactions) of the SGX Listing Rules, we can act as independent valuer.

03

Stage 3 · Post due diligenceValuation Update

We help you work through the due diligence findings and update the valuation for the adjustments agreed, before you sign.

Key risks we help you avoid
  • Due diligence findings not reflected in the price you pay
  • Disagreements over individual adjustments left unresolved until completion, leading to disputes
  • Value leaking away through liabilities or working capital shortfalls you end up funding after completion
In more detail

Due diligence usually leads to adjustments, for example to normalise earnings, to working capital, or for debt-like items found late in the process. Each one can move the price, and if they are not worked through carefully, you can end up paying for them after completion.


We review the financial due diligence reports and findings in detail and help you identify the items that may affect the valuation. This helps you discuss each adjustment with the seller and work out how to close the gap on each.

Once all parties have agreed and finalised the adjustments, we update the valuation to reflect them, and through sensitivity and scenario analysis show how much the key remaining risks could move the value, as a basis for discussing protections such as earn-outs, escrows and warranties with your legal and financial advisers.

04

Stage 4 · Post-completionPurchase Price Allocation and Impairment Testing

After the deal closes, we carry out the Purchase Price Allocation (PPA) under FRS 103 and the annual impairment testing of goodwill and other assets under FRS 36, built to meet audit and regulatory expectations.

Key risks we help you avoid
  • Financial statements that don't reflect the key intangible assets or the deal rationale
  • Intangibles not properly recognised and disclosed, so investors can't see the value created
  • Unexpectedly high amortisation or impairment charges that weigh on post-acquisition earnings
In more detail

Completing the deal is only part of the job. You need to allocate the purchase price across identifiable assets and goodwill, and then test goodwill and other assets for impairment every year. We prepare these valuations in line with FRS 103, FRS 36 and FRS 113.


A PPA also helps to show the market what you bought. If the key intangible assets, such as customer relationships, technology or brands, are not properly identified, recognised and disclosed, the financial statements may not reflect the rationale for the deal, and investors may not understand the value it created.

The PPA also drives future amortisation and impairment risk, which directly affects post-acquisition earnings. We work with you to get this right from the start, and closely with your auditors, so the conclusions are clearly documented and hold up to audit and regulatory review.

Other ways we help

  • Intangible asset valuations: brands, technology, customer relationships, patents and trademarks, including for Section 19B tax purposes
  • Disposals: valuations to support the sale of a business, a subsidiary or a stake

Evaluating an acquisition or investment?

Get in touch